A Phase I Study of Safety and Pharmacokinetics of Nevirapine in HIV-1 Infected Pregnant Women and Neonates Born to HIV-1 Infected Mothers
Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001
Trial Information
Current as of May 11, 2025
Completed
Keywords
ClinConnect Summary
Treatment of HIV-1 infected pregnant women during active labor may result in therapeutic levels of nevirapine in the neonate at the time of exposure to HIV-1 during parturition, decreasing the neonate's risk of infection.
Pregnant women in active labor receive single doses of oral nevirapine. The neonates of the first 4-6 (PER AMENDMENT 8/27/96, was 4) mothers receive no drug, while the neonates of the second 4-6 (PER AMENDMENT 8/27/96, was 4) patient cohort receive a single dose of nevirapine. If neonatal antiviral levels of nevirapine are not sustained for 7 days after the single dose, a...
Gender
FEMALE
Eligibility criteria
- • Inclusion Criteria
- Concurrent Medication:
- Allowed:
- • AZT (mothers and neonates).
- • Oral asthma inhalers (mothers).
- Concurrent Treatment:
- Allowed:
- • Phototherapy (neonates).
- MOTHERS must have:
- • HIV infection.
- • Estimated gestational age \>= 34 weeks.
- • No active opportunistic infection at study entry.
- PER AMENDMENT 8/27/96:
- • A pre-enrollment plasma HIV-1 RNA level greater than 10,000 copies/ml.
- • Exclusion Criteria
- Co-existing Condition:
- MOTHERS with the following symptoms or conditions are excluded:
- • Intrauterine growth retardation.
- • Fetal anomaly incompatible with life as determined by pre-entry ultrasound.
- • Participation during current pregnancy in any other therapeutic or vaccine perinatal trial.
- • Known hypersensitivity to any benzodiazepine.
- • Serious bacterial infection.
- Concurrent Medication:
- Excluded:
- • Any antiretroviral other than AZT.
- • Corticosteroids (other than oral asthma inhalers).
- • Anticoagulants.
- • Any clavulanic acid-containing formulation (e.g., Augmentin, Timentin).
- • Benzodiazepines other than study drug.
- • Phenobarbital.
- • Barbiturates.
- • Antacids.
- • Magnesium sulfate.
- Prior Medication:
- Excluded:
- • Prior nevirapine.
- • Current use of illicit substances and/or active chronic alcohol use.
About National Institute Of Allergy And Infectious Diseases (Niaid)
The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
San Francisco, California, United States
La Jolla, California, United States
Los Angeles, California, United States
Los Angeles, California, United States
San Francisco, California, United States
Chicago, Illinois, United States
Chicago, Illinois, United States
Boston, Massachusetts, United States
Boston, Massachusetts, United States
New York, New York, United States
San Juan, , Puerto Rico
Newark, New Jersey, United States
Farmington, Connecticut, United States
Worcester, Massachusetts, United States
Hartford, Connecticut, United States
Patients applied
Trial Officials
Sullivan JL
Study Chair
Sperling R
Study Chair
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials